5^th World Congress on Parkinsons & Huntington Disease August 29-31, 2019 Vienna, Austria

Biography:

M. Sabesan has completed his PhD from Bharathidasan university and post doctoral studies from Freiburg university,Germany.He worked as Prof and Head  with Dean ,Faculty of science,Annamalai university,India.He worked on PD and published 20 papers in this neurodegenerative diseases in the high impact factor journals.He guided 7 students for PhD in the same field.He has completed 4 major research projects in this subject.

Abstract:

Curcumin (diferulomethane),a polyphenol extracted from the plant Curcuma longa,is widely used in food both  in India and China.It is also used  in therapeutic uses.In this study  we used curcumin and its derivative first time to treat  neurodegenerative disease,Parkinsons disease.(PD)In this disease the increased reactive oxygen species(ROS)accumulation and oxidative damage to lipids,neucleic acids and proteins..Therapeutic use of curcumin for this neurodegerative disease appear multifactorial which regulates the enzymes,cytokines ,monoamine oxidase-B inhibition ,and transcription factors.We investigated Free radicals ,enzymatic and non enzymatic antioxidants in on methyl 4-phenyl 1, 2 ,3 4 tetra hydro pyridine(MPTP).In this model depletion of dopamine(DA) and DOPAC(3,4 dihydroxy phenyl acetic acid) occurs with increased activity of monamine oxidase(MOA-B). We used HPLC with electrochemical detection  to measure DA and DOPAC respectively while MAO-B was assayed  by spectroflourimetry using the conversion of fluorogenic substrate,kyuramine.Systemic administration of curcumin(80 mg/kg i.p) and tetrahydrocurcumin(60mg/kg ip) significantly reversed the MPTP induced depletion of DA and DOPAC.The MOA-B activity was also significantly inhibited by these compounds.The results showed that curcumin and its derivative reversed the MPTP induced depletion of DA and DOPAC which may in part be due to inhibition of MAO-B activity. This result also supported by free radical estimation, antioxidant assay and electron microscopical observations. In conclusion both curcumin  and its metabolite exert neuroprotection against MPTP induced neurotoxicity.

Biography:

Hatef Ghasemi Hamidabadi was graguated at Tehran University of Medical Sciences in 2011. I am member of German neurosciences and Immunogenetic Research Center. I published more than 25 articles in the field of stem cells.

Abstract:

Possible production of dopaminergic neurons from human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) is a big promise for neural tissue engineering and clinical treatment of neurodegenerative diseases, such as Parkinson’s disease. The main goal of the current study was to determine the differentiation potential of HUC-MSCs toward dopaminergic neuron-like cells. HUC-MSCs were isolated and cultured on Matrigel and induced with a cocktail of dopaminergic neuron differentiation factors. The capacity of HUC-MSCs for differentiation into dopaminergic neuron-like cells was assessed by real-time PCR, immunocytochemistry and high-performance liquid chromatography (HPLC) and compared to the cells differentiated in cell culture plate. The differentiation assessment at the level of mRNA and protein illustrated that Matrigel significantly increased the markers related to dopaminergic neurons compared to the culture plate. Taken together, the results suggest that HUC-MSCs can successfully differentiate into dopaminergic neuron-like cells on Matrigel and may have a promising potential for treatment of dopaminergic neuron-related diseases.

Biography:

Maryam Nazm Bojnordi has completed his PhD at the age of 33 years from Tarbiat Modares University. She is the member of scientific staff of Anatomical science in Mazandaran University of Medical Sciences. She has published more than 32 papers and has been serving as an editorial board member of journals.

Abstract:

The limited capcacity of the central nervous system in repairmen of neuronal population such as dopaminergic neuron cells suggests stem cell therapy for neurogenesis in Parkinson’s disease. Also, stem cell therapy accompanied with scaffolds, is a promising treatment in neural tissue engineering to induce neural differentiation in damaged tissue of brain. Here we fabricated and used a silk Nano fibrous scaffold for differentiation of Embryonic stem like cells in to dopaminergic neuron cells. Embryonic stem cells, were cultured on fabricated Silk scaffolds. The neural differentiation was induced using a modified technique includes; culturing in the presence of Retinoic acid and neurobasal medium with 10 ng/ml Epidermal Growth Factor, 20 ng/ml basic Fibroblastic Growth Factor for 10 days. The neural differentiation was investigated using the evaluation of specific markers via immunocytochemistry and real-time technique. Our dates proved that silk scaffold support the differentiation of Embryonic stem cells cells in to dopaminergic neuron. The expression of neural specific markers were significantly higher in the cells were cultured on fabricated Silk scaffolds in compare to monolayer control group. Electrospun silk Nano fibrous scaffold is considered as a biological substitutes for neural differentiation of stem cells that is a crucial step in tissue engineering for neural tissue repair and regeneration.

Biography:

She is currently serving as Lecturer in the College of Nursing, Foundation University, Islamabad, Pakistan. I have had the oppertunity and honour to review several articles and supervised 4 dessertations at graduate level. Currently aspiring to enroll in an esteemed programe for gaining a degree in research.

Abstract:

The review is aimed at all those involved in care of patients suffering from parkinson’s disease, regardless of their place of work: traditional hospitalization, home, day hospital, nursing home, retirement homes etc. The current study discusses the care of patients suffering from parkinson’s disease by setting nursing goals which includes improving functional mobility, maintaining independence in performing ADLs, achieving optimal bowel elimination, attaining and maintaining acceptable nutritional status, achieving effective communication and developing positive coping mechanisms. Parkinson's disease is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra. From the clinical point of view, the motor symptoms include: involuntary tremor, bradykinesia and rigidity. The prevalence of the disease is around 10 million people in the world. The neurological degeneration triggered by this disease gradually causes great disability in patients. This progression can be reduced to a limited extent through the available medication. However, due to the current incurability of the pathology is essential the presence of a nurse figure that addresses effectively the different needs presented by patients and their caregivers, since these are extended, in addition to the physiological factor, to the social, economic, psychological and behavioral of these people. Nursing is presented as a fundamental part for the care of patients suffering from the disease and their caregivers, establishing interventions aimed at improving the patient's quality of life. Nursing is presented as a fundamental part for the care of patients suffering from the disease and their caregivers, establishing interventions aimed at improving the patient's quality of life. The patient who needs this type of treatment requires the application of specific care. For this reason, it is imperative to update the level of care as an orientation and provide a guide that can be useful in clinical practice and allows identifying possible nursing problems. A correct approach requires an individualized care plan to the patient's personal situation, to favor their self-care with optimum quality to adress the areas highlighted in the figure below.

Biography:

Abstract:

Introduction: Strategies to treat patients with Parkinson’s disease cannot stop the progression. In Cuba, the Center for Molecular Immunology is a cutting edge scientific center where recombinant human erythropoietins with low sialic acid (NeuroEPO) are produced.  We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin.

Objective: Assess safety and the positive results of the cognitive tests of recombinant human erythropoietin with low sialic acid in a group of Parkinson’s disease patients.

Methods: The study was conducted in PD patients from the outpatient clinic of CIREN, including n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The study employed an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Safety was evaluated by recording adverse events (by intensity and causality). Hematological parameters and blood pressure were also measured because of their direct relationship to the medication’s action.

Results: Five patients experienced mild adverse events with a possible causal relationship in the five patients that were neither life-threatening nor required hospitalization. The results in the study showed a positive response to the cognitive functions in patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention which could be interpreted as an effect of the neuroprotective properties of these molecules.